Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia
A Pilot Study to Assess the Safety, Tolerability and Efficacy of Selectin Inhibitor Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia
Sponsor: GlycoMimetics Incorporated
Terminated
No more eligible patients were available.
A PHASE1/PHASE2 clinical study on COVID-19 Pneumonia, this trial is terminated or withdrawn. The trial is conducted by GlycoMimetics Incorporated and has accumulated 6 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Jan 2022 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Oct 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlycoMimetics Incorporated
- Lena Napolitano, MD
For direct contact, visit the study record on ClinicalTrials.gov .